688289.SH
圣湘生物
SSE · Healthcare · Medical - Instruments & Supplies · CN
CNY 14.90
−5.58%Year over year
Reported trailing growth
- Revenue
- +3.9%
- EBITDA
- —
- EBIT
- -45.3%
- EPS
- -46.5%
- Free cash flow
- —
- Operating cash flow
- -40.8%
Forward estimates
Based on analyst estimates
- Revenue
- -75.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -36.6%
- EBITDA
- -44.0%
- EBIT
- -55.7%
- Net income
- -53.2%
- EPS
- -53.2%
- Free cash flow
- -26.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026